Replies to post #133 on Pure Bioscience, Inc. (PURE)

[investorsa]

PURE Bioscience Names Craig Johnson as Chief Financial Officer
Business Wire
on FacebookShare on TwitterShare on DiggShare on LifestreamPURE Bioscience, Inc. (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announces the appointment of Craig Johnson as Chief Financial Officer, effective August 1, 2011. Mr. Johnson has more than 15 years' experience as a senior financial executive in the healthcare industry.

Mr. Johnson has been Chief Financial Officer of two publicly traded companies: NovaDel Pharma, a drug delivery company, and TorreyPines Therapeutics, a biopharmaceutical company. Prior to that, he was Chief Financial Officer and Senior Vice President of Operations for MitoKor, a drug discovery company.

Mr. Johnson currently serves on the board of directors, and as chairman of the audit committees, of Ardea Biosciences and Adamis Pharmaceuticals, both of which are publicly traded biotechnology companies based in San Diego.

Michael L. Krall, President and CEO of PURE Bioscience, said, “We are delighted to attract a professional of Craig’s caliber to PURE. He is an outstanding financial and operations executive with a proven record in managing growth companies. He has the background and expertise to help PURE develop its many new business opportunities and execute our multi-faceted growth strategy.”

Mr. Johnson commented, “I believe PURE has tremendous opportunity and is poised for remarkable growth. I look forward to working with Mike and the team at PURE to fully develop and realize the potential of the company’s SDC technology platform.”

Early in his career, Mr. Johnson served as a senior financial executive for several early-stage technology companies, and he also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received his BBA in accounting from the University of Michigan.